Clinical trial No longer in our active list Phase 3 Interventional Ages 18 to 130 Men only

Comparing Saruparib to placebo in men with metastatic prostate cancer receiving hormonal treatment

Official title: A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)

Run by AstraZeneca · NCT06120491 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing whether a new drug called Saruparib can help men with advanced prostate cancer feel better when combined with hormonal treatments compared to a placebo.

More Metastatic Castration-resistant Prostate Cancer trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 130 Years
SexMen only
Enrollment1800 (estimated)
SponsorAstraZeneca
Industry-sponsored
Locations410 sites (Chandler, Arizona and 409 other locations)
Trial IDNCT06120491 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include men aged 18 and older with histologically confirmed metastatic castration-sensitive prostate adenocarcinoma.

Probably not a fit

Patients with small cell, neuroendocrine, sarcomatoid, spindle cell, or signet cell histology will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to demonstrate the superiority of Saruparib (AZD5305) combined with physician's choice of new hormonal agents (NHA) compared to a placebo with NHA in men with metastatic castration-sensitive prostate cancer (mCSPC). Approximately 1800 adult participants will be randomized into two cohorts based on their homologous recombination repair mutation (HRRm) status. Participants will receive their assigned treatment and undergo regular tumor evaluations until disease progression or treatment cessation. An independent data monitoring committee will oversee the safety and tolerability of the treatment.

Why it matters

Potential benefit: If successful, this treatment could significantly improve radiographic progression-free survival for men with metastatic castration-sensitive prostate cancer.

How similar studies have gone: Other studies have shown promising results with similar approaches in treating metastatic prostate cancer, indicating potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male ≥ 18 years of age.
* Histologically documented prostate adenocarcinoma which is de novo or recurrent and castration-sensitive. Participants with pathologic features of small cell, neuroendocrine, sarcomatoid, spindle cell, or signet cell histology are not eligible.
* Metastatic disease as documented by the investigator prior to randomisation, with clear evidence of ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion that is suitable for repeated assessment with CT and/or MRI.
* Participant is receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy starting ≥ 14 days and \< 4 months prior to randomisation.
* ECOG performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomisation.
* Provision of FFPE tumour tissue sample and blood sample (for ctDNA).
* Confirmed HRRm status by central tumour tissue and/or ctDNA test is required to determine cohort eligibility.
* Adequate organ and bone marrow function as described in study protocol.
* Participants must not father children or donate sperm from signing ICF, during the study intervention and for 6 months after the last dose of study intervention.
* Participants must use a condom from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners.

Exclusion Criteria:

* Participants with a history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). In case there is no clinical MDS/AML suspicion, no specific screening for MDS/AML (by BM/bone biopsy) is required.
* Participants with any known predisposition to bleeding.
* Any history of persisting (\> 2 weeks) severe cytopenia.
* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305 and/or the assigned NHA.
* History of another primary malignancy, with exceptions.
* Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy.
* Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.
* Cardiac criteria, including history of arrhythmia and cardiovascular disease.
* Any prior anticancer pharmacotherapy or surgery for metastatic prostate cancer, with exceptions.
* Prior treatment within 14 days with blood product support or growth factor support.
* Participants who are unevaluable for both bone and soft tissue progression.

Where it's running

  • Research Site
    New Haven, Connecticut, United States
    Recruiting
  • Research Site
    Durham, North Carolina, United States
    Recruiting
  • Research Site
    Providence, Rhode Island, United States
    Recruiting
  • Research Site
    Myrtle Beach, South Carolina, United States
    Recruiting
  • Research Site
    San Antonio, Texas, United States
    Recruiting
  • Research Site
    Salt Lake City, Utah, United States
    Recruiting
Show 44 more locations
  • Research Site
    Chermside, Australia
    Recruiting
  • Research Site
    Melbourne, Australia
    Recruiting
  • Research Site
    South Brisbane, Australia
    Recruiting
  • Research Site
    Krems, Austria
    Recruiting
  • Research Site
    Linz, Austria
    Recruiting
  • Research Site
    Vienna, Austria
    Recruiting
  • Research Site
    Vienna, Austria
    Recruiting
  • Research Site
    Calgary, Alberta, Canada
    Recruiting
  • Research Site
    Calgary, Alberta, Canada
    Recruiting
  • Research Site
    Abbotsford British Columbia, British Columbia, Canada
    Recruiting
  • Research Site
    Abbotsford British Columbia, British Columbia, Canada
    Recruiting
  • Research Site
    Kelowna, British Columbia, Canada
    Recruiting
  • Research Site
    Vancouver, British Columbia, Canada
    Recruiting
  • Research Site
    Kingston, Ontario, Canada
    Recruiting
  • Research Site
    Mississauga, Ontario, Canada
    Recruiting
  • Research Site
    Newmarket, Ontario, Canada
    Recruiting
  • Research Site
    Ottawa, Ontario, Canada
    Recruiting
  • Research Site
    Toronto, Ontario, Canada
    Recruiting
  • Research Site
    Toronto, Ontario, Canada
    Recruiting
  • Research Site
    Chicoutimi, Quebec, Canada
    Recruiting
  • Research Site
    Greenfield Park, Quebec, Canada
    Recruiting
  • Research Site
    Montreal, Quebec, Canada
    Recruiting
  • Research Site
    Montreal, Quebec, Canada
    Recruiting
  • Research Site
    Montreal, Quebec, Canada
    Recruiting
  • Research Site
    Québec, Quebec, Canada
    Recruiting
  • Research Site
    Saskatoon, Saskatchewan, Canada
    Recruiting
  • Research Site
    Bordeaux, France
    Recruiting
  • Research Site
    Clermont-Ferrand, France
    Recruiting
  • Research Site
    Lyon, France
    Recruiting
  • Research Site
    Montpellier, France
    Recruiting
  • Research Site
    Nice, France
    Recruiting
  • Research Site
    Paris, France
    Recruiting
  • Research Site
    Poitiers, France
    Recruiting
  • Research Site
    Hamburg, Germany
    Recruiting
  • Research Site
    Heidelberg, Germany
    Recruiting
  • Research Site
    Münster, Germany
    Recruiting
  • Research Site
    Nürtingen, Germany
    Recruiting
  • Research Site
    Tübingen, Germany
    Recruiting
  • Research Site
    Milan, Italy
    Recruiting
  • Research Site
    Rozzano, Italy
    Recruiting
  • Research Site
    George Town, Malaysia
    Recruiting
  • Research Site
    Johor Bahru, Malaysia
    Recruiting
  • Research Site
    Kota Kinabalu, Malaysia
    Recruiting
  • Research Site
    Kuala Lumpur, Malaysia
    Recruiting

+360 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.